A High Molecular Weight Protein Extract of Mastobranchus indicus (Mi-64) Having Antiarthritic Activity in Experimental Animals
- 154 Downloads
Mi-64, a high molecular weight protein (130 kDa), obtained from the tissue homogenate of marine polychaete (Mastobranchus indicus) collected from the Indian Sunderban has antiarthritic activity in experimental animals. The FCA-induced arthritis model was developed in Wistar albino rats to evaluate the antiarthritic effects of Mi-64. After FCA induction, the rats were treated with Mi-64 (0.25 and 0.5 mg kg−1 body weight) for 10 days. We have determined the paw/ankle swellings, urinary hydroxyproline and glucosamine, serum acid and alkaline phosphatases to assess the antiarthritic activity. The levels of interleukin-1 beta (IL-1β), IL-6, cytokine-induced neutrophil chemoattractant-1 (CINC-1), tumor necrosis factor-alpha (TNF-α), and IL-10 were measured by ELISA. Results showed that Mi-64 significantly reduced paw/ankle swellings and restored the urinary hydroxyproline/glucosamine and serum phosphatases. Mi-64 significantly inhibited the overproduction of IL-1β, IL-6, CINC-1, and TNF-α and augmented IL-10 production. The data suggest that Mi-64 produced significant antiarthritic effects that may be mediated by balancing the pro- and anti-inflammatory cytokines.
KEY WORDSmarine polychaete Mastobranchus indicus Mi-64 adjuvant-induced arthritis
This study was partially supported by University Grant Commission under University with Potential for Excellence (Modern Biology) Scheme (Sanction no. UGC/199/UPE/07), New Delhi, India.
- 1.Baslow, M.N. 1969. Marine Pharmacology. Baltimore: Williams and Wilkins.Google Scholar
- 2.Halvorson, D.J., J.R. Dupree, and E.S. Porubsky. 1998. Management of chronic sinusitis in the adult cystic fibrosis patient. Annals of Otology, Rhinology and Laryngology 107: 946–952.Google Scholar
- 6.Jarosz, J., and Z. Gliński. 1997. Earthworm immune responses. Folia Biologica (Krakow) 45: 1–9.Google Scholar
- 15.Williams, R. O. 2005. Models of rheumatoid arthritis. Ernst Schering Res Found Workshop, 89–117.Google Scholar
- 19.Barnes, P. M., E. Powell-Griner, K. McFann, and R.L. Nahin. 2004. Complementary and alternative medicine use among adults: United States, 2002. Advance Data, 1-19.Google Scholar
- 33.Yasuda, M., T. Okabe, J. Itoh, S. Takekoshi, H. Hasegawa, H. Nagata, R.Y. Osamura, and K. Watanabe. 2000. Differentiation of necrotic cell death with or without lysosomal activation: Application of acute liver injury models induced by carbon tetrachloride (CCl4) and dimethylnitrosamine (DMN). Journal of Histochemistry and Cytochemistry 48: 1331–1339.PubMedCrossRefGoogle Scholar
- 40.Canetti, C.A., B.P. Leung, S. Culshaw, I.B. McInnes, F.Q. Cunha, F.W. Liew, and C.A. Cannetti. 2003. IL-18 enhances collagen-induced arthritis by recruiting neutrophils via TNF-alpha and leukotriene B4. Journal of Immunology 171: 1009–1015.Google Scholar
- 42.Nanki, T., K. Nagasaka, K. Hayashida, Y. Saita, and N. Miyasaka. 2001. Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Journal of Immunology 167: 5381–5385.Google Scholar
- 43.Joosten, L.A., M.M. Helsen, F.A. van de Loo, and W.B. van den Berg. 1996. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis and Rheumatism 39: 797–809.PubMedCrossRefGoogle Scholar
- 44.Moreland, L.W., M.H. Schiff, S.W. Baumgartner, E.A. Tindall, R.M. Fleischmann, K.J. Bulpitt, A.L. Weaver, E.C. Keystone, D.E. Furst, P.J. Mease, E.M. Ruderman, D.A. Horwitz, D.G. Arkfeld, L. Garrison, D.J. Burge, C.M. Blosch, M.L. Lange, N.D. McDonnell, and M.E. Weinblatt. 1999. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Annals of Internal Medicine 130: 478–486.PubMedGoogle Scholar
- 46.Nishimoto, N., K. Yoshizaki, K. Maeda, T. Kuritani, H. Deguchi, B. Sato, N. Imai, M. Suemura, T. Kakehi, N. Takagi, and T. Kishimoto. 2003. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. Journal of Rheumatology 30: 1426–1435.PubMedGoogle Scholar